Pharmacogenetics of Deoxycytidine Kinase: Identification and Characterization of Novel Genetic Variants
- 1 December 2007
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 323 (3) , 935-945
- https://doi.org/10.1124/jpet.107.128595
Abstract
Deoxycytidine kinase (DCK) is a rate-limiting enzyme in the activation of nucleoside analogs such as cytarabine (ara-C), gemcitabine, clofarabine, and others. The present study was undertaken to identify and to determine the functional consequences of genetic variants in DCK. We sequenced 1.5 kilobases of the DCK proximal promoter and all seven coding exons in International HapMap Project panels (n = 90 each) with European (Centre d' Etude du Polymorphisme Humain; CEPH) or African (Yoruba people in Ibadan, Nigeria; YRI) ancestry. Sixty-four genetic polymorphisms, including three nonsynonymous coding changes (I24V, A119G, and P122S) were identified. Compared with DCK-wild-type (WT) protein, the activity of the recombinant DCK24Val, DCK119Gly, and DCK122Ser proteins was 85 ± 5, 66 ± 3, and 43 ± 4%, respectively. DCK119Gly and DCK122Ser mutants had lower Km (p < 0.01) and Vmax (p < 0.001) compared with DCK-WT protein. Lymphoblast cell lines from subjects heterozygous for the coding changes had significantly lower DCK activity compared with homozygous WT subjects. Ethnic differences were observed, with African ancestry subjects demonstrating significantly higher DCK mRNA expression compared with subjects with European ancestry. In both CEPH and YRI subjects, the C allele of a 3′-untranslated region single-nucleotide polymorphism (SNP) (35708 C>T) was significantly associated with lower DCK mRNA expression. This SNP was strongly linked with other intronic SNPs, forming a major haplotype block in both ethnic groups. In an exploratory analysis, the 35708C allele was also associated with lower blast ara-C-5′-triphosphate (ara-CTP) levels in acute myeloid leukemia patients receiving ara-C as continuous infusion. These results suggest that genetic variation in DCK influences its activity and expression and may predict the variability observed in intracellular levels of the ara-C active metabolite ara-CTP.Keywords
This publication has 19 references indexed in Scilit:
- Novel deoxycytidine kinase gene polymorphisms: a population screening study in Caucasian healthy volunteersEuropean Journal of Clinical Pharmacology, 2006
- Docking simulation with a purine nucleoside specific homology model of deoxycytidine kinase, a target enzyme for anticancer and antiviral therapyBioorganic & Medicinal Chemistry, 2005
- Problems Related to Resistance to Cytarabine in Acute Myeloid LeukemiaLeukemia & Lymphoma, 2004
- PCR isolation and cloning of novel splice variant mRNAs from known drug target genesGenomics, 2004
- Interim Comparison of a Continuous Infusion Versus a Short Daily Infusion of Cytarabine Given in Combination With Cladribine for Pediatric Acute Myeloid LeukemiaJournal of Clinical Oncology, 2002
- Potential mechanisms of resistance to cytarabine in AML patientsLeukemia Research, 2001
- Expression of Deoxycytidine Kinase (dCK) Gene in Leukemic Cells in Childhood: Decreased Expression of dCK Gene in Relapsed LeukemiaLeukemia & Lymphoma, 1998
- Low Expression of the Deoxycytidine Kinase (dCK) Gene in a 1-β-D- Arabinofuranosylcytosine-Resistant Human Leukemic Cell Line KY-RaLeukemia & Lymphoma, 1994
- Selective assays for thymidine kinase 1 and 2 and deoxycytidine kinase and their activities in extracts from human cells and tissuesBiochemical and Biophysical Research Communications, 1992
- Lethality of human myeloblasts correlates with the incorporation of arabinofuranosylcytosine into DNA.Proceedings of the National Academy of Sciences, 1981